STAT

Welcome to the first edition of the STAT Health Tech newsletter

STAT Health Tech is our weekly guide to how tech is transforming health care and the life sciences.

STAT Health Tech is our new weekly guide to how tech is transforming health care and the life sciences. Sign up here to receive it in your inbox every Wednesday.

Good morning. We’re thrilled to bring you the first edition of STAT Health Tech!

Every Wednesday, we’ll steer you through the crowded intersection of health care and technology. You’ll get the latest on how tech giants like Amazon and Alphabet and startups like Akili and Insitro are trying to disrupt the delivery of care and the development of drugs. And we’ll give you our take on the underlying financial, ethical, and privacy issues.

Why did we decide to launch a newsletter on this topic? Because advanced artificial intelligence and novel software tools are challenging the status quo in every corner of the industry. Our goal is not only to update you on the news, but also

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks